Abstract:Selection of the treatments most likely to combat a patient's tumor is a central aim of precision oncology. We are currently developing a functional precision oncology program at the University of Utah and Huntsman Cancer Institute that combines the multi-omic characterization of a patient's tumor with the functional screening of relevant drug candidates in patient-derived organoid tumor models to identify which drugs are uniquely capable of combating the patient's cancer. Here we present our model-based approach for utilizing the multi-omic tumor data to computationally predict the patient's response to each drug. In this approach, we first identify the genomic and transcriptomic vulnerabilities of the tumor as genes harboring somatic DNA mutations or copy number changes (from paired tumor/normal WGS/WES DNA sequencing data), as well as genes whose expression levels have been significantly altered in the tumor (based on bulk or single-cell RNA sequencing data). Second, using targeting information from drug-gene interaction databases (DGIdb) we compile a list of genes targeted by each drug relevant in the patient's treatment. Third, we utilize gene interaction database knowledge (KEGG) to construct a gene interaction graph to link each drug's gene targets with all of the tumor's vulnerability genes. We then identify all gene interaction paths connecting specific drug target genes with specific vulnerability genes; and score each path and combine all path-specific scores for the target-vulnerability gene pair. Subsequently, we further combine all pairwise scores across all drug target genes and all tumor vulnerability genes and determine the statistical significance of the resulting score by sampling the background distribution of such scores across random drugs, target genes, and vulnerability genes. We have applied our algorithm to predict drug response in advanced breast cancer patients as well as using publicly available tumor cell line data (GDSC2). We have found a high level of concordance between our computational prediction and organoid/cell line screening results, clearly separating sensitive and non-sensitive models. Using Bayesian probability, we compare the drug-specific score distributions of sensitive and non-sensitive models and are able to identify sensitive cell lines/patients with high accuracy. By encapsulating available information on direct gene-gene interactions, the drug's direct gene targets and the collected omic vulnerabilities of the tumor, our model is not only capable of predicting sensitivity to both targeted and chemotherapy agents, but can also provide a mechanistic understanding for the targeting of the tumor. Our approach will be validated and fine-tuned on a large cohort of breast and brain cancer patients as well as patient PDX models, interrogating gene-target interactions to identify novel relevant target genes/pathways. Citation Format: Szabolcs Tarapcsak, Yi Qiao, Xiaomeng Huang, Tony Di Sera, Matthew H. Bailey, Bryan E. Welm, Alana L. Welm, Gabor T. Marth. Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2723.

[Bilateral spontaneous pseudo-tumoral cytosteatonecrosis of the breast. Apropos of 2 cases in men].

Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Understanding therapeutic tolerance through a mathematical model of drug-induced resistance

Modeling multi-mutation and drug resistance: analysis of some case studies

Drug Resistance and Gene Amplification Potential Regulated by Transforming Growth Factor β1 Gene Expression

Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model

Model-based Analysis of Response and Resistance Factors of Cetuximab Treatment in Gastric Cancer Cell Lines

Mathematical modeling and dynamic analysis for cancer resistance incorporating persister cells

Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid

Investigating the development of chemotherapeutic drug resistance in cancer: A multiscale computational study

Abstract 2723: Model-based cancer therapy selection by linking tumor vulnerabilities to drug mechanism

A Hybrid Cellular Automaton Model of Solid Tumor Growth and Bioreductive Drug Transport

Biphasic Mathematical Model of Cell–Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells

Mathematical modeling and computational prediction of cancer drug resistance

Mechanistic modeling of cell viability assays with in silico lineage tracing

Mechanistic Model for Cancer Growth and Response to Chemotherapy

Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach

Dosage optimization for reducing tumor burden using a phenotype-structured population model with a drug-resistance continuum

A Comprehensive Model to Differentiate Spontaneous, Drug-induced, and CSCs-related Drug Resistance

Growth‐rate model predicts in vivo tumor response from in vitro data